马俊媛;温梦;马佳;田蕾;王绍宁;徐晖;

• 1:沈阳药科大学制药工程学院
• 2:锦州医科大学药学院
• 3:沈阳药科大学药学院

摘要(Abstract)：

目的以水溶性的高分子材料为载体,制备白藜芦醇载药膜剂,改善BCS II类药物白藜芦醇的溶解度、释放速率及生物利用度。方法采用溶液流延法制备白藜芦醇载药膜剂,分别采用光学显微镜法和扫描电子显微镜法对膜剂外观进行观察;傅里叶变换红外光谱法、X-射线粉末衍射法对载药膜剂进行表征;在纯水、模拟胃液和模拟肠液中,考察白藜芦醇药物释放行为;同时以白藜芦醇原料药混悬液为对照进行大鼠体内药动学研究。结果白藜芦醇膜剂表面光滑平整,傅里叶变换红外光谱法及X-射线粉末衍射法显示,白藜芦醇在膜剂内以分子或无定形形式存在;膜剂中白藜芦醇的释放不受介质种类的影响,释放速率及累计释放量远高于白藜芦醇原料药;大鼠体内药动学研究结果显示,膜剂显著提高白藜芦醇吸收速率。结论膜剂相较于原料药,体外释放速率,累积释放量,体内吸收速率方面均显著提高。

关键词(KeyWords)： 白藜芦醇;膜剂;体外释放;药动学

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 马俊媛;温梦;马佳;田蕾;王绍宁;徐晖;

Email:

DOI: 10.14066/j.cnki.cn21-1349/r.2019.0500

参考文献(References)：

• [1] PERRONE D,FUGGETTA M,ARDITO F,et al.Resveratrol (3,5,4″-trihydroxystilbene) and its properties in oral diseases (Review)[J].Experimental and Therapeutic Medicine,2017,14(1):3-9.
• [2] HUANG,X T,LI X,XIE M L,et al.Resveratrol:review on its discovery,anti-leukemia effects and pharmacokinetics [J].Chemico Biological Interactions,2019,306(28):29-38.
• [3] WANG H,ZHAO H X,ZHANG X J,et al.Preparation of resveratrol pH-sensitive copolymer micelles and pharmacokinetics in rats [J].Journal of Shenyang Pharmaceutical University,2016,34(5):339-344.
• [4] AMRI A,CHAUMEIL J C,SFAR S,et al.Administration of resveratrol:what formulation solutions to bioavailability limitations?[J].Journal of Controlled Release,2012,158(2):182-193.
• [5] CHANG C W,WONG C Y,WU Y T,et al.Development of a solid dispersion system for improving the oral bioavailability of resveratrol in rats [J].Eur J Drug Metab Pharmacokinet,2017,42(2):239-249.
• [6] National Pharmacopoeia Commission.Pharmacopoeia of the People′s Republic of China:Part IV [M].Beijing:China Medical Science and Technology Press,2015:124.
• [7] LIU X Y,LIU S J,SUN K M,et al.Research and application progress of oral film [J].Chinese Pharmacy(中国药房),2015,26(10):1420-1423.
• [8] NISHIGAKI M,K KAWAHARA,M NAWA,et al.Development of fast dissolving oral film containing dexamethasone as an antiemetic medication:clinical usefulness [J].Int J Pharm,2012,424(1/2):12-17.
• [9] YELLANKI S,S JAGTAP,R MASAREDDY.Dissofilm:a novel approach for delivery of phenobarbital;design and characterization [J].J Young Pharm,2011,3(3):181-188.
• [10] SUN W,PAN B .Effect of micro-environment modification and polymer type on the in vitro dissolution behavior and in vivo performance of amorphous solid dispersions [J].European Journal of Pharmaceutical Sciences,2017,104(8):240-254.
• [11] YANG Z,Argenziano M,Salamone P,et al.Preclinical pharmacokinetics comparison between resveratrol 2-hydroxypropyl-β-cyclodextrin complex and resveratrol suspension after oral administration [J].Journal of Inclusion Phenomena and Macrocyclic Chemistry,2016,86(3):263-271.
• [12] DAS S,LIN H S,HO P C,et al.The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol [J].Pharmaceutical Research,2008,25(11):2593-2600.
• [13] ZHOU Z,W LI,SUN W J,et al.Resveratrol cocrystals with enhanced solubility and tabletability [J].International Journal of Pharmaceutics,2016,509(1):391-399.
• [14] ELOY J O,MARCHETTI J M.Solid dispersions containing ursolic acid in poloxamer 407 and PEG 6000:a comparative study of fusion and solvent methods [J].Powder Technology,2014,253(12):98-106.
• [15] HOMAYOUNI A,SADEGHI F,NOKHODCHI A,et al.Preparation and characterization of celecoxib solid dispersions;comparison of poloxamer-188 and PVP-K30 as carriers [J].Iran J Basic Med Sci,2014,17(5):322-31.
• [16] ANDREWS G P,ABU-DIAK O,KUSMANTO F,et al.Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions [J].J Pharm Pharmacol,2010,62(11):1580-1590.
• [19] XU J,LUO K Q.Enhancing the solubility and bioavailability of isoflavone by particle size reduction using a supercritical carbon dioxide-based precipitation process [J].Chemical Engineering Research and Design,2014,92(11):2542-2549.
• [20] GROO A C,PASCALE M D E,VOISIN-CHIRET A S,et al.Comparison of 2 strategies to enhance pyridoclax solubility:nanoemulsion delivery system versus salt synthesis [J].European Journal of Pharmaceutical Sciences,2017,97:218-226.
• [21] LIU T,YUAN X,JIA T,et al.Polymeric prodrug of bufalin for increasing solubility and stability:Synthesis and anticancer study in vitro and in vivo [J].International Journal of Pharmaceutics,2016,506(1):382-393.
• [22] PACHECO P A,RODRIGUES L N C,FERREIRA J F S,et al.Inclusion complex and nanoclusters of cyclodextrin to increase the solubility and efficacy of albendazole [J].Parasitology Research,2018,117(3):705-712.
• [23] MENG F,FERREIRA R,ZHANG F.Effect of surfactant level on properties of celecoxib amorphous solid dispersions [J].Journal of Drug Delivery Science and Technology,2019,49:301-307.
• [24] SUN D D,WEN H,TAYLOR L S.Non-sink dissolution conditions for predicting product quality and in?vivo performance of supersaturating drug delivery systems [J].Journal of Pharmaceutical Sciences,2016,105(9):2477-2488.
• [25] HUANG J G.Study on the effect of pharmaceutical excipients to inhibit the intestinal P-glycoprotein drug pump(药用辅料抑制肠道P-糖蛋白药泵作用研究) [D].Huazhong University of Science and Technology,2008.
• [26] GOTTESMAN M M.Biochemistry of multidrug resistance mediated by the multidrug transporter [J].Annual Review of Biochemistry,1998,62(1):385-427.